Trospium chloride

Last updated

Trospium chloride
Trospium chloride.svg
Clinical data
Pronunciation /ˈtroʊspiəm/
TROHS-pee-əm
Trade names Regurin, Sanctura, others [1]
AHFS/Drugs.com Monograph
Routes of
administration 		By mouth
Drug class Antimuscarinic (peripherally selective)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 50–85%
Elimination half-life 20 hours
Identifiers
  • 3‑(2‑Hydroxy-2,2‑diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'‑pyrrolidin]-1'‑ium chloride
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.030.784 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C25H30ClNO3
Molar mass 427.97 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)(c2ccccc2)C(=O)O[C@@H]3C[C@@H]5CC[C@H](C3)[N+]45CCCC4
  • InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+ Yes check.svgY
  • Key:OYYDSUSKLWTMMQ-JKHIJQBDSA-N Yes check.svgY
   (verify)

Trospium chloride is a muscarinic antagonist used to treat overactive bladder. [3] It has side effects typical of this class of drugs, namely dry mouth, stomach upset, and constipation; these side effects cause problems with people taking their medicine as directed. However it doesn't cause central nervous system side effects like some other muscarinic antagonists. [4]

Contents

Chemically it is a quaternary ammonium cation which causes it to stay in periphery rather than crossing the blood–brain barrier. [5] It works by causing the smooth muscle in the bladder to relax. [3]

It was patented in 1966 and approved for medical use in 1974. [6] It was first approved in the US in 2004, and an extended release version was brought to market in 2007. It became generic in the EU in 2009, and the first extended-release generic was approved in the US in 2012.

Medical uses

Trospium chloride is used for the treatment of overactive bladder with symptoms of urge incontinence and frequent urination. [3] [4] [2]

It should not be used with people who retain urine, who have severe digestive conditions, myasthenia gravis, narrow-angle glaucoma, or tachyarrhythmia. [3]

It should be used with caution in people who have problems with their autonomous nervous system (dysautonomia) or who have gastroesophageal reflux disease, or in whom fast heart rates are undesirable, such as people with hyperthyroidism, coronary artery disease and congestive heart failure. [3]

There are no adequate and well-controlled studies of trospium chloride in pregnant women and there are signs of harm to the fetus in animal studies. The drug was excreted somewhat in the milk of nursing mothers. [3] The drug was studied in children. [3]

Side effects

Side effects are typical of gastrointestinal effects of anticholinergic drugs, and include dry mouth, indigestion, and constipation. These side effects lead to problems with adherence, especially for older people. [4] The only CNS side effect is headache, which was very rare. Tachycardia is a rare side effect. [3]

Mechanism of action

Trospium chloride is a muscarinic antagonist. Trospium chloride blocks the effect of acetylcholine on muscarinic receptors organs that are responsive to the compounds, including the bladder. [3] Its parasympatholytic action relaxes the smooth muscle in the bladder. [4] Receptor assays showed that trospium chloride has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. [3]

Pharmacokinetics

After oral administration, less than 10% of the dose is absorbed. Mean absolute bioavailability of a 20 mg dose is 9.6% (range: 4.0 to 16.1%). Peak plasma concentrations (Cmax) occur between 5 and 6 hours post-dose. Mean Cmax increases greater than dose-proportionally; a 3-fold and 4-fold increase in Cmax was observed for dose increases from 20 mg to 40 mg and from 20 mg to 60 mg, respectively. AUC exhibits dose linearity for single doses up to 60 mg. Trospium chloride exhibits diurnal variability in exposure with a decrease in Cmax and AUC of up to 59% and 33%, respectively, for evening relative to morning doses. [7]

Administration with a high fat meal resulted in reduced absorption, with AUC and Cmax values 70 to 80% lower than those obtained when trospium chloride was administered while fasting. Therefore, it is recommended that trospium chloride should be taken at least one hour prior to meals or on an empty stomach. [7]

Protein binding ranged from 50 to 85% when concentration levels of trospium chloride (0.5 to 50 ng/mL) were incubated with human serum in vitro. The 3H-trospium chloride ratio of plasma to whole blood was 1.6:1. This ratio indicates that the majority of 3H-trospium chloride is distributed in plasma. The apparent volume of distribution for a 20 mg oral dose is 395 (± 140) liters. [7]

The metabolic pathway of trospium in humans has not been fully defined. Of the 10% of the dose absorbed, metabolites account for approximately 40% of the excreted dose following oral administration. The major metabolic pathway is hypothesized as ester hydrolysis with subsequent conjugation of benzylic acid to form azoniaspironortropanol with glucuronic acid. Cytochrome P450 is not expected to contribute significantly to the elimination of trospium. Data taken from in vitro human liver microsomes investigating the inhibitory effect of trospium on seven cytochrome P450 isoenzyme substrates (CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4) suggest a lack of inhibition at clinically relevant concentrations. [7]

The plasma half-life for trospium chloride following oral administration is approximately 20 hours. After oral administration of an immediate-release formulation of 14C-trospium chloride, the majority of the dose (85.2%) was recovered in feces and a smaller amount (5.8% of the dose) was recovered in urine; 60% of the radioactivity excreted in urine was unchanged trospium. The mean renal clearance for trospium (29 L/hour) is 4-fold higher than average glomerular filtration rate, indicating that active tubular secretion is a major route of elimination for trospium. There may be competition for elimination with other compounds that are also renally eliminated. [7]

Chemical properties

Anticholinergic drugs used to treat overactive bladder were all amines as of 2003. Quaternary ammonium cations in general are more hydrophilic than other amines and don't cross membranes well, so they tend to be poorly absorbed from the digestive system, and to not cross the blood–brain barrier. Oxybutynin, tolterodine, darifenacin, and solifenacin are tertiary amines while trospium chloride and propantheline are quaternary amines. [5]

History

The synthesis of trospium was described by scientists from Dr. Robert Pfleger Chemische Fabrik GmbH, Heinz Bertholdt, Robert Pfleger, and Wolfram Schulz, in US. Pat. No. 3,480,626 (the US equivalent to DE119442), and its activity was first published in the literature in 1967. [8] [9]

The first regulatory approval was granted in Germany in August 1999 to Madaus AG for Regurin 20 mg Tablets. [10] : 13  Madaus is considered the originator for regulatory filings worldwide. [11] The German filing was recognized throughout Europe under the Mutual Recognition Procedure. [10] : 13 

Madaus licensed the US rights to trospium chloride to Interneuron in 1999 and Interneuron ran clinical trials in the US to win FDA approval. [12] [13] Interneuron changed its name to Indevus in 2002 [14] Indevus entered into a partnership with Odyssey Pharmaceuticals, a subsidiary of Pliva, to market the drug in April 2004, [15] and won FDA approval for the drug, which it branded as Sanctura, in May 2004. [16] [17] The approval earned Indevus a milestone payment of $120M from Pliva, which had already paid Indevus $30 million at signing; the market for overactive bladder therapies was estimated to be worth $1.1 billion in 2004. [18] In 2005 Pliva exited the relationship, selling its rights to Esprit Pharma, [19] and in September 2007 Allergan acquired Esprit, and negotiated a new agreement with Indevus under which Allergan would completely take over the US manufacturing, regulatory approvals, and marketing. [20] A month before, Indevus had received FDA approval for an extended release formulation that allowed once a day dosing, Sanctura XR. [21] Indevus had developed intellectual property around the extended release formulation which it licensed to Madaus for most of the world. [20]

In 2012 the FDA approved the first generic version of the extended release formulation, granting approval to the ANDA that Watson Pharmaceuticals had filed in 2009. [22] Annual sales in the US at that time were $67M. [23] European patents had expired in 2009. [24]

As of 2016, the drug is available worldwide under many brand names and formulations, including oral, extended release, suppositories, and injections. [1]

Society and culture

Marketing rights to the drug became subject to parallel import litigation in Europe in the case of Speciality European Pharma Ltd v Doncaster Pharmaceuticals Group Ltd / Madaus GmbH (Case No. A3/2014/0205) which was resolved in March 2015. Madaus had exclusively licensed the right to use the Regurin trademark to Speciality European Pharma Ltd. In 2009, when European patents expired on the drug, Doncaster Pharmaceuticals Group, a well known parallel importer, which had been selling the drug in the UK under another label, Ceris, which was used in France, began to put stickers on their packaging with the Regurin name. Speciality and Madaus sued and initially won based on the argument that 90% of prescriptions were already generic, but Doncaster appealed and won the appeal based on the argument that it could not charge a premium with a generic label. The case has broad implications for trade in the EU. [24] [25]

Research

In 2007 Indevus partnered with Alkermes to develop and test an inhaled form of trospium chloride as a treatment for COPD; it was in Phase II trials at that time. [26]

Related Research Articles

<span class="mw-page-title-main">Metoclopramide</span> Medication

Metoclopramide is a medication used for stomach and esophageal problems. It is commonly used to treat and prevent nausea and vomiting, to help with emptying of the stomach in people with delayed stomach emptying, and to help with gastroesophageal reflux disease. It is also used to treat migraine headaches.

<span class="mw-page-title-main">Ipratropium bromide</span> Type of anticholinergic

Ipratropium bromide, sold under the trade name Atrovent among others, is a type of anticholinergic medication which is applied by different routes: inhaler, nebulizer, or nasal spray, for different reasons.

Aptalis was a company in the pharmaceutical industry. In January 2014, the company was acquired by Forest Laboratories for $675 million. Through a series of acquisitions, the company is now a contract development and manufacturing organization and rebranded as Adare Phama Solutions, headquartered in Lawrenceville, New Jersey.

<span class="mw-page-title-main">Bioequivalence</span> Similarity between preparations of a drug

Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.

<span class="mw-page-title-main">Pliva</span> Croatian pharmaceutical company

Pliva d.o.o. is a pharmaceutical company based in Zagreb, Croatia that primarily manufactures and sells generic drugs. It is a subsidiary of Teva Pharmaceuticals.

<span class="mw-page-title-main">Armodafinil</span> Eugeroic medication

Armodafinil, sold under the brand name Nuvigil, is a wakefulness-promoting medication which is used to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and shift work disorder. It is also used off-label for certain other indications. The drug is taken by mouth.

<span class="mw-page-title-main">Oxybutynin</span> Medication for overactive bladder

Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder. It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time. It works similar to tolterodine, darifenacin, and solifenacin, although it is usually preferred over these medications. It is sometimes used off-label for treatment of hyperhidrosis, or excessive sweating. It has also been used off-label to treat bed wetting in children, but this use has declined, as it is most likely ineffective in this role. It is taken by mouth or applied to the skin.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Solifenacin</span> Chemical compound

Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency.

<span class="mw-page-title-main">Tapentadol</span> Opioid analgesic of benzenoid class

Tapentadol, brand names Nucynta among others, is a centrally acting opioid analgesic of the benzenoid class with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours.

<span class="mw-page-title-main">Fesoterodine</span> Chemical compound

Fesoterodine is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.

<span class="mw-page-title-main">Xanomeline</span> Chemical compound

Xanomeline is a small molecule muscarinic acetylcholine receptor agonist that was first synthesized in a collaboration between Eli Lilly and Novo Nordisk as an investigational therapeutic being studied for the treatment of central nervous system (CNS) disorders.

<span class="mw-page-title-main">Pimavanserin</span> Atypical antipsychotic medication

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, but rather is a selective inverse agonist of the serotonin 5-HT2A receptor.

<span class="mw-page-title-main">Hydrocodone/ibuprofen</span> Combination drug

Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively.

<span class="mw-page-title-main">GW Pharmaceuticals</span>

GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.

<span class="mw-page-title-main">Eluxadoline</span> Chemical compound

Eluxadoline, sold under the brand names Viberzi and Truberzi, is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.

<span class="mw-page-title-main">Vibegron</span> Medication

Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. Vibegron is a selective beta-3 adrenergic receptor agonist.

<span class="mw-page-title-main">Xanomeline/trospium chloride</span> Medication

Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. It contains xanomeline, a muscarinic agonist; and trospium chloride, a muscarinic antagonist. Xanomeline is a functionally preferring muscarinic M4 and M1 receptor agonist. Trospium chloride is a non-selective muscarinic antagonist.

References

  1. 1 2 "International brands of trospium". Drugs.com. Retrieved 13 May 2016.
  2. 1 2 FDA "Trospium chloride label" (PDF). U.S. Food and Drug Administration. January 2011.
  3. 1 2 3 4 5 6 7 8 9 10 "Regurin XL 60mg". UK eMC. 3 July 2015.
  4. 1 2 3 4 Biastre K, Burnakis T (February 2009). "Trospium chloride treatment of overactive bladder". Ann Pharmacother. 43 (2): 283–95. doi:10.1345/aph.1L160. PMID   19193592. S2CID   20102756.
  5. 1 2 Pak RW, Petrou SP, Staskin DR (December 2003). "Trospium chloride : a quaternary amine with unique pharmacologic properties". Curr Urol Rep. 4 (6): 436–40. doi:10.1007/s11934-003-0023-1. PMID   14622495. S2CID   4512769.
  6. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 446. ISBN   9783527607495.
  7. 1 2 3 4 5 Doroshyenko O, Jetter A, Odenthal KP, Fuhr U (2005). "Clinical pharmacokinetics of trospium chloride". Clin Pharmacokinet. 44 (7): 701–20. doi:10.2165/00003088-200544070-00003. PMID   15966754. S2CID   10968270.
  8. ↑ US 6974820 which cites US 3480626 and Bertholdt H, Pfleger R, Schulz W (1967). "[On azoniaspire-compounds. 2. Preparation of esterified azoniaspire-compounds of nortropan-3-alpha- or 3-beta-ol (1)]". Arzneimittelforschung. 17 (6): 719–26. PMID   5632538.
  9. ↑ DEpatent 1194422,Bertholdt H, Pfleger R, Schulz W,"[Verfahren zur Herstellung von Azoniaspironortropanderivaten] (A process for preparing azonia-spirono-tropane derivatives)",issued 10 June 1965, assigned to Dr. Robert Pfleger Chemische Fabrik GmbH
  10. 1 2 "Trospium Chloride 20mg Film-Coated Tablets, Public Assessment Report" (PDF). Medicines and Healthcare products Regulatory Agency. 7 April 2011.
  11. ↑ "Trospium chloride". AdisInsight. Springer Nature Switzerland AG.
  12. ↑ Miller J (23 September 2002). "Indevus to apply for new drug status for incontinence drug". Boston Business Journal.
  13. ↑ Herper M (25 September 2002). "A Biotech Phoenix Could Be Rising". Forbes.
  14. ↑ "Indevus Pharmaceuticals, Inc., Formerly Interneuron, to Begin Trading on Nasdaq". Indevus Press Release. 2 April 2002.
  15. ↑ "Indevus and PLIVA Sign Co-Promotion and Licensing Agreement for SANCTURA -Trospium Chloride". Indevus Press Release. 7 April 2004. Archived from the original on 27 August 2021. Retrieved 14 May 2016.
  16. ↑ "Sanctura (trospium chloride)". CenterWatch. Retrieved 13 May 2016.
  17. ↑ "Indevus Announces FDA Approval Of Sanctura". Indevus Press Release. 28 May 2004.
  18. ↑ Osterweil N (28 May 2004). "FDA approves Indevus' Sanctura". for First Word Pharma.
  19. ↑ "Novartis, P&G enter agreement for OAB drug". Urology Times. 21 July 2005.
  20. 1 2 "Indevus Announces Allergan as New Partner for Sanctura Brand". Indevus Press Release. 19 September 2007.
  21. ↑ "Indevus' Sanctura XR approved by US FDA". The Pharma Letter. 13 August 2007.
  22. ↑ "ANDA 091289 approval letter" (PDF). U.S. Food and Drug Administration. 12 October 2012.
  23. ↑ "Watson's Generic Sanctura XR Receives FDA Approval". Watson Press Release. 12 October 2012.
  24. 1 2 "Court takes a permissive approach to parallel importers within the EU". Lexology. 6 March 2015.
  25. ↑ R.P.C. (2015) 132 (7): 521-540. doi: 10.1093/rpc/rcv039
  26. ↑ "Alkermes, Indevus testing COPD drug". UPI. 25 April 2007.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.